Latent Health vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $80M Series A (Mar 2026) co-led by Spark Capital and Transformation Capital. 2M+ patients/year. Partners with 50% of top 20 US health systems. McKesson Ventures strategic investor.
About
Latent Health is a medication access and prior authorization automation platform that uses its Clinical Reasoning Engine to ingest EHR data, interpret drug approval criteria, and automate the full medication access workflow end-to-end. The company raised $80 million in Series A financing in March 2026 co-led by Spark Capital and Transformation Capital, with McKesson Ventures, General Catalyst, and Y Combinator as co-investors. The platform serves 2 million+ patients annually and is partnered with 50% of the top 20 US health systems.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.